Mineralys Therapeutics (MLYS) Preferred Stock Liabilities (2022)

Mineralys Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $117.7 million for Q4 2022.

• Preferred Stock Liabilities for Q4 2022 came in at $117.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $117.7 million (changed N/A YoY), and the FY2022 annual result was $117.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $117.7 million for Q4 2022 at Mineralys Therapeutics, roughly flat from $117.7 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $117.7 million in Q3 2022 to a low of $41.0 million in Q1 2022.